<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00922623</url>
  </required_header>
  <id_info>
    <org_study_id>MUS 90028-0622/1 Supplement</org_study_id>
    <nct_id>NCT00922623</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Belotero® in Subjects With Fitzpatrick Phototypes IV Through VI</brief_title>
  <official_title>A Multicenter Study of The Safety and Effectiveness of Dermal Filler, Belotero®, After Mid-to-Deep Dermal Implantation for Correction of Moderate to Severe Facial Wrinkles (Such as Nasolabial Folds) Over 24 Weeks in Subjects With Fitzpatrick Phototype Scores of IV, V, and VI.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz North America, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to assess how safe and effective an investigational product, Belotero® is in
      people with all skin types with facial wrinkles, such as nasolabial folds. Nasolabial folds
      are wrinkles on the face that go from outside of the nostrils to the edges of the mouth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Fitzpatrick Skin Phototype Scale goes from number 1 (I), which is the very lightest skin
      tone, to number 6 (VI) which is the very darkest skin tone. This study is to determine the
      safety and effectiveness of Belotero® in people with skin phototypes of 1(I)thru 6 (VI).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With Product-related Adverse Events.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Adverse events considered possibly, probably, or definitely related to study product are summarized by body system and MedDRA preferred term.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Facial Wrinkles</condition>
  <arm_group>
    <arm_group_label>Belotero®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Belotero®</intervention_name>
    <description>Hyaluronic acid dermal filler, Belotero®, single use syringe, injected into mid to deep dermal layer</description>
    <arm_group_label>Belotero®</arm_group_label>
    <other_name>Nasolabial folds</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Had reviewed and signed a statement of Informed Consent and HIPAA authorization. In
             addition, subjects were asked to provide a separate release for use of their
             photographs in publications. Subjects had a right to refuse the photo release without
             jeopardizing their eligibility to participate in the study.

          2. Was 18 to 75 years of age, of any race or sex.

          3. If female, was post-menopausal for at least one year; or had undergone a hysterectomy;
             or a tubal ligation; or if of childbearing potential, had negative urine pregnancy
             test results and agreed to use an approved method of birth control throughout the
             study (ie, oral/systemic contraceptives, intrauterine device [IUD], or spermicide in
             combination with a barrier method of contraception), or was abstinent, or was in a
             monogamous relationship with a partner who had had a vasectomy.

          4. Had bilateral nasolabial folds with a severity of 2 or 3 on the wrinkle severity
             rating scale (SRS) as assessed by the Evaluator Investigator.

          5. Subjects were to have been rated IV, V, or VI on the Fitzpatrick Skin Phototype Scale.

          6. Had adequate understanding of the language (spoken and written English or Spanish) and
             was willing to comply with the study requirements.

        Exclusion Criteria:

          1. A personal history of allergic/anaphylactic reactions including hypersensitivity to
             local anesthetics (eg, lidocaine, etc), hyaluronic acid (HA) preparations, and/or
             gram-positive bacterial protein.

          2. A known history of keloids or bleeding disorders.

          3. Leukoderma (vitiligo) or a family history of leukoderma or other pigmentary disorders.

          4. An active inflammatory process in the nasolabial fold area (skin eruptions such as
             cysts, pimples, rashes, cancerous/pre-cancerous lesions, psoriasis, neurodermatitis,
             or any other active skin disease) or severe scarring that might interfere with study
             assessments.

          5. If female, pregnant, planning to become pregnant during the study, or breast feeding.

          6. Planned to undergo major facial surgery during the course of the study (eg,
             rhinoplasty [with or without implant], facelift, congenital defect repair, etc).

          7. Clinically important disease, as judged by the investigator, within 3 months of the
             study (eg, significant laboratory test abnormalities, myocardial infarct, stroke,
             cancer, connective tissue diseases [scleroderma, systemic lupus erythematous],
             systemic infection, uncontrolled diabetes, etc.), including those with medical
             conditions that might require the use of immunosuppressive medications during the
             trial (eg, severe, uncontrolled asthma, rheumatoid arthritis, autoimmune diseases,
             etc).

          8. Severe physical, neurological or mental disease.

          9. Excessive facial hair that might interfere with the evaluation of the wrinkle
             assessments.

         10. Any systemic or dermatologic disorder, which, in the opinion of the investigator,
             would interfere with the study results or increase the risk of AEs.

         11. Had used exclusionary medications/treatments.

         12. Participation in a clinical investigation within the 30 days prior to the first
             planned device administration or during this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rhoda Narins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Surgery and Laser Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pearl E Grimes</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valerie Callender</name>
      <address>
        <city>Mitchellville</city>
        <state>Maryland</state>
        <zip>20721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeanine B Downie</name>
      <address>
        <city>Montclair</city>
        <state>New Jersey</state>
        <zip>07042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2009</study_first_submitted>
  <study_first_submitted_qc>June 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2009</study_first_posted>
  <results_first_submitted>December 22, 2011</results_first_submitted>
  <results_first_submitted_qc>December 22, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 30, 2012</results_first_posted>
  <disposition_first_submitted>October 12, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>October 12, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 21, 2011</disposition_first_posted>
  <last_update_submitted>April 19, 2013</last_update_submitted>
  <last_update_submitted_qc>April 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nasolabial folds</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Belotero®</title>
          <description>Belotero® injection into both nasolabial folds of Fitzpatrick IV, V, VI subjects.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Belotero®</title>
          <description>Belotero® injection into both nasolabial folds of Fitzpatrick IV, V, VI subjects.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="93"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.5" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Product-related Adverse Events.</title>
        <description>Adverse events considered possibly, probably, or definitely related to study product are summarized by body system and MedDRA preferred term.</description>
        <time_frame>24 weeks</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all subjects enrolled and treated with Belotero (ITT principle).</population>
        <group_list>
          <group group_id="O1">
            <title>Belotero, Left Nasolabial Fold</title>
            <description>Belotero injected into the Left Nasolabial Fold of the Face</description>
          </group>
          <group group_id="O2">
            <title>Belotero, Right Nasolabial Fold</title>
            <description>Belotero injected into the Right Nasolabial Fold of the Face</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Product-related Adverse Events.</title>
          <description>Adverse events considered possibly, probably, or definitely related to study product are summarized by body system and MedDRA preferred term.</description>
          <population>The Full Analysis Set (FAS) consisted of all subjects enrolled and treated with Belotero (ITT principle).</population>
          <units>percentage of subjects with AEs.</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Belotero, Left Nasolabial Fold</title>
        </group>
        <group group_id="E2">
          <title>Belotero, Right Nasolabial Fold</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Injection site nodule</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Injection site discoloration</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any proposed press release, announcement, disclosure for publication, whether or not in writing, prepared by or on behalf of Consultant as part of services under this Agreement or that relates to the work performed hereunder must be reviewed and approved in writing by Merz prior to dissemination.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Merz Aesthetics, Inc.</name_or_title>
      <organization>Merz Aesthetics, Inc.</organization>
      <phone>650-286-4000</phone>
      <email>clinicaltrials@merzaesthetics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

